Mark Robertson-Tessi

15PUBLICATIONS
58CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Virtual and mixed realityCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 22, 2026
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexity.

|Dec 19, 2025
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.

Sandhya Prabhakaran, Chandler D Gatenbee, Mark Robertson-Tessi

|Oct 17, 2025
Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making.

Kevin R Scibilia, Kit Gallagher, M A Masud

|Jul 26, 2023
Virtual alignment of pathology image series for multi-gigapixel whole slide images.

Chandler D Gatenbee, Ann-Marie Baker, Sandhya Prabhakaran

|May 19, 2023
Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.

Jill Gallaher, Maximilian Strobl, Jeffrey West

|May 23, 2022
Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.

Maximilian A R Strobl, Jill Gallaher, Jeffrey West

Pageof 3

Frequent Collaborators

15 joint publications

Alexander R A Anderson

6 joint publications

Jeffrey West

5 joint publications

Maximilian Strobl

5 joint publications

Robert Gatenby